个体化制定促卵泡素δ起始剂量可降低总体卵巢过度刺激综合征风险和/或减少额外预防性干预的需求:三个刺激周期的累积数据
本文为ESTHER-1与ESTHER-2试验的二次分析,比较个体化促卵泡素δ与传统促卵泡素α方案在最多三个卵巢刺激周期中对卵巢过度刺激综合征(OHSS)风险的影响。个体化促卵泡素δ方案显著降低中/重度OHSS和/或预防性干预的发生率(P=0.018),获益主要集中于预处理抗苗勒管激素(AMH)最高四分位患者(P=0.012)。
要点
- 个体化促卵泡素δ较促卵泡素α显著降低中/重度OHSS和/或预防性干预发生率(P=0.018)。
- 获益主要见于预处理AMH最高四分位患者(P=0.012)。
- 分别评估时,促卵泡素δ显著降低中/重度OHSS(P=0.036)及预防性干预(P=0.044)。
核心结论
- 个体化促卵泡素δ给药方案较传统促卵泡素α方案降低中/重度OHSS风险及预防性干预发生率。
- 按AMH四分位分析显示,这些统计学显著差异主要由预处理AMH水平最高的患者驱动。
研究设计与样本
- 研究为一项随机、评估者盲法试验(ESTHER-1,NCT01956110)和另一项允许最多两个额外周期的试验(ESTHER-2,NCT01956123)中三个卵巢刺激周期的二次分析。
- 共1326名18-40岁女性在第1周期随机接受促卵泡素δ或促卵泡素α治疗,其中513名进入第2周期,188名进入第3周期。
- 促卵泡素δ和促卵泡素α的剂量根据前一周期的卵巢反应维持或调整。
主要发现
- 在最多三个卵巢刺激周期中,个体化促卵泡素δ较传统促卵泡素α显著降低中/重度OHSS和/或预防性干预(P=0.018)。
- 在预处理AMH最高四分位患者中观察到最大获益(P=0.012)。
- 分别评估时,个体化促卵泡素δ较促卵泡素α显著降低中/重度OHSS发生率(P=0.036)和预防性干预发生率(P=0.044)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Is individualization of dosing with follitropin delta in sequential ovarian stimulation cycles an effective preventive strategy for ovarian hyperstimulation syndrome risk? If so, for which patients does an individualized strategy provide the greatest OHSS risk reduction and/or the need for additional preventive interventions? DESIGN: A secondary analysis of three ovarian stimulation cycles in IVF/intracytoplasmic sperm injection patients included in one randomized, assessor-blinded trial comparing two recombinant FSH preparations (ESTHER-1, NCT01956110), and a second trial in women undergoing up to two additional cycles (ESTHER-2, NCT01956123). Of 1326 women (aged 18-40 years) randomized and treated with follitropin delta or alfa in cycle 1, 513 continued to cycle 2 and 188 to cycle 3. Follitropin delta and alfa doses were maintained/adjusted according to ovarian response in the previous cycle. RESULTS: Individualized dosing with follitropin delta significantly reduced moderate/severe OHSS and/or preventive interventions (P=0.018) versus conventional dosing with follitropin alfa in patients undergoing up to three ovarian stimulation cycles. The greatest benefit was observed in patients in the highest anti-Müllerian hormone (AMH) quartile (P=0.012). On evaluating separately, individualized dosing with follitropin delta significantly lowered the incidences of moderate/severe OHSS (P=0.036) and preventive interventions (P=0.044) versus follitropin alfa. CONCLUSION: An individualized follitropin delta dosing regimen decreased the risk of moderate/severe OHSS as well as the incidence of preventive interventions versus a conventional follitropin alfa regimen. An analysis per AMH quartile indicated that these statistically significant differences are driven mainly by patients with the highest pretreatment AMH levels.
引用
- Fernández-Sánchez M, Visnova H, Yuzpe A, et al. Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reprod Biomed Online. 2018. PMID: 30713022. doi:10.1016/j.rbmo.2018.12.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。